Top stories in hematology/oncology: FDA says cellphone radiation poses no cancer risk, researchers advance novel pancreatic cancer treatment
Click Here to Manage Email Alerts
One of the top stories in hematology/oncology last week was about a recent FDA report that concluded there is “insufficient evidence” to link cellphone radiation exposure to cancer.
In other news, researchers at Stony Brook University’s Renaissance School of Medicine are advancing an enzyme-targeting drug that could prolong survival in patients with metastatic pancreatic cancer to phase 3 development.
Read these and other top stories in hematology/oncology below:
FDA finds ‘insufficient evidence’ to link cellphone radiation to cancer
The FDA, after reviewing more than a decade of published scientific research, reaffirmed its conclusion that there is no risk for cancer from exposure to radio waves emitted by cellphones. Read more.
Researchers hope to confirm ‘remarkable results’ of novel drug combination for advanced pancreatic cancer
Researchers at Stony Brook University’s Renaissance School of Medicine have developed an enzyme-targeting drug that could prolong survival for patients with metastatic pancreatic cancer. Read more.
Just one dose of HPV vaccine may confer durable cervical cancer protection
One dose of the HPV vaccine appeared to be as effective as multiple doses in preventing preinvasive cervical disease among adolescents vaccinated between ages 15 and 19 years, according to results of a retrospective study published in Cancer. Read more.
Pembrolizumab-chemotherapy combination appears effective in metastatic triple-negative breast cancer
The addition of pembrolizumab to first-line chemotherapy significantly extended progression-free survival among patients with metastatic triple-negative breast cancer whose tumors express PD-L1, according to topline data released by the agent’s manufacturer. Read more.
History of dengue infection increases risk for leukemia
Individuals with a history of dengue virus infection had more than twice the risk for developing leukemia as those without a history of dengue, according to results of a population-based study published in Cancer Epidemiology, Biomarkers & Prevention. Read more.